Sign Up
Stories
Mundipharma Approves REZZAYO® for Invasive Fungal Infections
Share
ANJESO Drug Insight and Market Forecast
Advancing OSE-279: Promising Cancer Trea...
Basilea Pharmaceutica Ltd reports strong...
Overview
API
Mundipharma has secured European approval for REZZAYO® (rezafungine), a significant advancement in addressing the lack of new treatment options for invasive fungal infections, leading to high mortality rates and morbidity.
Ask a question
How might the approval of REZZAYO® impact the management of invasive fungal infections in adults?
In what ways could the approval of REZZAYO® influence the development of future treatments for infectious diseases?
What are the potential implications of this advancement for the healthcare industry and patient care?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Sep 2023
Oct 2023
Nov 2023
Dec 2023
Coverage